Natalizumab-treated patient characteristics.

Only the long-lasting and relevant therapies are reported. The interval between IFNβ 1a or GA therapies and natalizumab was at least of 30 days. plmMS received MTX from February 2004 to November 2006, nMS3 from February 2003 to March 2005 and nMS4 from July 2004 to February 2007.**There was no trend of EDSS up- or downwards.***Time point in which PML was diagnosed. Four different samples were obtained over a 1-month period. For the other time points and in all other patients, only one biological sample was analyzed.F, female; M, male; y, years; w, weeks; IFN, interferon; MTX, mitoxantrone; GA, glatiramer acetate; na, not available.仅报道具有临床持久性与相关性的治疗方案。干扰素β1a（IFNβ 1a）或醋酸格拉替雷（glatiramer acetate，GA）治疗与那他珠单抗（natalizumab）之间的洗脱间隔至少为30天。plmMS患者于2004年2月至2006年11月接受米托蒽醌（mitoxantrone，MTX）治疗，nMS3患者于2003年2月至2005年3月接受该治疗，nMS4患者于2004年7月至2007年2月接受该治疗。**扩展残疾状态量表（EDSS）无升高或降低趋势。** *进行性多灶性白质脑病（PML）的确诊时间点：在1个月内采集了4份不同的生物学样本。其余时间点及所有其他患者仅分析了1份生物学样本。F代表女性（female）；M代表男性（male）；y代表年（years）；w代表周（weeks）；IFN代表干扰素（interferon）；MTX代表米托蒽醌（mitoxantrone）；GA代表醋酸格拉替雷（glatiramer acetate）；na代表无可用数据（not available）。